Share on StockTwits

InterMune (NASDAQ:ITMN) CEO Daniel G. Welch unloaded 4,565 shares of the company’s stock on the open market in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $40.06, for a total value of $182,873.90. Following the transaction, the chief executive officer now directly owns 98,116 shares of the company’s stock, valued at approximately $3,930,527. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of analysts have recently weighed in on ITMN shares. Analysts at William Blair raised their price target on shares of InterMune from $41.00 to $48.00 in a research note on Thursday, May 22nd. Separately, analysts at ING Group upgraded shares of InterMune from a “market perform” rating to a “buy” rating in a research note on Monday, May 19th. They now have a $41.00 price target on the stock. Finally, analysts at Leerink Swann upgraded shares of InterMune from a “market perform” rating to an “outperform” rating in a research note on Monday, May 19th. They now have a $41.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. InterMune currently has a consensus rating of “Buy” and a consensus price target of $39.08.

Shares of InterMune (NASDAQ:ITMN) traded down 1.31% on Monday, hitting $39.10. The stock had a trading volume of 1,333,822 shares. InterMune has a 52-week low of $9.32 and a 52-week high of $41.19. The stock has a 50-day moving average of $34. and a 200-day moving average of $23.93. The company’s market cap is $3.866 billion.

InterMune (NASDAQ:ITMN) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.59) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.62) by $0.03. The company had revenue of $30.30 million for the quarter, compared to the consensus estimate of $28.24 million. During the same quarter in the prior year, the company posted ($0.64) earnings per share. The company’s quarterly revenue was up 188.6% on a year-over-year basis. On average, analysts predict that InterMune will post $-2.34 earnings per share for the current fiscal year.

InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.